CR11089A - Derivados de carboxamida imidazolidina como modulares de p2x7 - Google Patents

Derivados de carboxamida imidazolidina como modulares de p2x7

Info

Publication number
CR11089A
CR11089A CR11089A CR11089A CR11089A CR 11089 A CR11089 A CR 11089A CR 11089 A CR11089 A CR 11089A CR 11089 A CR11089 A CR 11089A CR 11089 A CR11089 A CR 11089A
Authority
CR
Costa Rica
Prior art keywords
modular
carboxamide derivatives
imidazolidine carboxamide
receptor
imidazolidine
Prior art date
Application number
CR11089A
Other languages
English (en)
Inventor
Paul John Beswick
David Kenneth Dean
Robert James Gleave
Andrew Peter Moses
Daryl Peter Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0706501A external-priority patent/GB0706501D0/en
Priority claimed from GB0720653A external-priority patent/GB0720653D0/en
Priority claimed from GB0805272A external-priority patent/GB0805272D0/en
Priority claimed from GB0805504A external-priority patent/GB0805504D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR11089A publication Critical patent/CR11089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invencion se refiere a un compuesto de formula (I) o una sal farmaceuticamente aceptable del mismo: los compuestos o sales modulan la funcion del receptor P2X7 y son capaces de antagonizar los efectos de ATP en el receptor P2X7 (antagonistas del receptor P2X7).
CR11089A 2007-04-03 2009-11-03 Derivados de carboxamida imidazolidina como modulares de p2x7 CR11089A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0706501A GB0706501D0 (en) 2007-04-03 2007-04-03 Novel compounds
GB0720653A GB0720653D0 (en) 2007-10-22 2007-10-22 Novel compounds
GB0805272A GB0805272D0 (en) 2008-03-20 2008-03-20 Novel compounds
GB0805504A GB0805504D0 (en) 2008-03-26 2008-03-26 Compounds

Publications (1)

Publication Number Publication Date
CR11089A true CR11089A (es) 2010-03-08

Family

ID=39673302

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11089A CR11089A (es) 2007-04-03 2009-11-03 Derivados de carboxamida imidazolidina como modulares de p2x7

Country Status (15)

Country Link
US (1) US7932282B2 (es)
EP (1) EP2142512A2 (es)
JP (1) JP2010523524A (es)
KR (1) KR20090127435A (es)
CN (1) CN101679291A (es)
AU (1) AU2008234855B2 (es)
BR (1) BRPI0809930A2 (es)
CA (1) CA2682649A1 (es)
CR (1) CR11089A (es)
DO (1) DOP2009000231A (es)
EA (1) EA200970912A1 (es)
IL (1) IL201202A0 (es)
MA (1) MA31352B1 (es)
MX (1) MX2009010759A (es)
WO (1) WO2008119825A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000117A (es) * 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
CN102471284A (zh) * 2009-07-30 2012-05-23 弗·哈夫曼-拉罗切有限公司 作为p2x7调节剂的二氢嘧啶酮酰胺
CA2783236C (en) * 2009-12-08 2020-03-10 Vanderbilt University Improved methods and compositions for vein harvest and autografting
US20130195919A1 (en) 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
PL2804865T3 (pl) 2012-01-20 2016-06-30 Idorsia Pharmaceuticals Ltd Heterocykliczne pochodne amidowe jako antagoniści receptora p2x7
CN104812749B (zh) 2012-12-12 2016-12-14 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
JP6295270B2 (ja) 2012-12-18 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP6282016B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
CA2897459C (en) 2013-01-22 2021-03-02 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
KR102424709B1 (ko) 2016-05-31 2022-07-22 칼비스타 파마슈티컬즈 리미티드 혈장 칼리크레인 저해제로서 피라졸 유도체
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
MX2022015581A (es) 2020-06-17 2023-01-24 Merck Sharp & Dohme Llc 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8.
CN115650920B (zh) * 2022-11-16 2023-03-31 山东金城柯瑞化学有限公司 制备药物中间体(4s)-1-甲基-2-氧代咪唑啉-4-羧酸叔丁酯的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5024287A (es) 1973-06-28 1975-03-15
JP2830528B2 (ja) 1991-07-25 1998-12-02 東洋インキ製造株式会社 シート状物保持装置
SE9704546D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
MX2009000117A (es) 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.

Also Published As

Publication number Publication date
AU2008234855A1 (en) 2008-10-09
WO2008119825A3 (en) 2008-12-11
DOP2009000231A (es) 2009-11-15
WO2008119825A2 (en) 2008-10-09
AU2008234855B2 (en) 2011-01-20
EA200970912A1 (ru) 2010-02-26
JP2010523524A (ja) 2010-07-15
CA2682649A1 (en) 2008-10-09
EP2142512A2 (en) 2010-01-13
MX2009010759A (es) 2009-10-28
US7932282B2 (en) 2011-04-26
KR20090127435A (ko) 2009-12-11
MA31352B1 (fr) 2010-05-03
BRPI0809930A2 (pt) 2014-10-07
US20100075968A1 (en) 2010-03-25
CN101679291A (zh) 2010-03-24
IL201202A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
CR11089A (es) Derivados de carboxamida imidazolidina como modulares de p2x7
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
UY33227A (es) Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
AR097079A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
CO6531452A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
ATE519764T1 (de) Spiroindolinon-derivate
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
UY31463A1 (es) Inhibidores de péptido desformilasa
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
UY35211A (es) Compuestos tricíclicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)